Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Optipharm Co., Ltd. (153710:KRX), powered by AI.
Optipharm Co., Ltd. is currently trading at ₩4,670. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Optipharm Co., Ltd. on Alpha Lenz.
Optipharm Co., Ltd.'s P/E ratio is -27.4.
“Optipharm Co., Ltd. trades at a P/E of -27.4 (undervalued) with modest ROE of -9.5%. 3Y revenue CAGR of 11.8% highlights clear growth momentum.”
Ask for details →Optipharm Co., Ltd. operates as a pharmaceutical company primarily engaged in the development, production, and distribution of healthcare and pharmaceutical products. It focuses on producing a wide array of medications and health-related supplements aimed at improving patient health and meeting diverse medical needs. The company plays a crucial role in the healthcare industry, providing innovative solutions that cater to a broad spectrum of health conditions. Optipharm Co., Ltd. is committed to research and development, ensuring it stays at the forefront of medical advancements. By maintaining stringent quality controls and regulatory compliance, the company assures the efficacy and safety of its products. In the financial markets, Optipharm Co., Ltd. holds significance as part of the pharmaceutical sector, often attracting attention from stakeholders interested in the health and biotechnological advancements. Its impact extends to various segments, including hospitals, pharmacies, and direct patient care, emphasizing its importance within the supply chain. Overall, Optipharm Co., Ltd. reflects the ongoing global demand for reliable health solutions and positions itself as an integral player in advancing public health initiatives.
“Optipharm Co., Ltd. trades at a P/E of -27.4 (undervalued) with modest ROE of -9.5%. 3Y revenue CAGR of 11.8% highlights clear growth momentum.”
Ask for details →Optipharm Co., Ltd. (ticker: 153710) is a company listed on KRX in the Healthcare sector (Diagnostics & Research). Market cap is $68.5B.
The current price is ₩4,670 with a P/E ratio of -27.41x and P/B of 2.7x.
ROE is -9.48% and operating margin is -10.80%. Annual revenue is $22.3B.